Share Prices & Company Research

Market News

01 Dec 2023 | 12:01

Proteome Sciences issues profit warning after project delays

(Sharecast News) - Proteome Sciences, the AIM-listed protein sequencing contract research organisation, has warned it will swing to a net loss this year with full-year sales lower than expected. The company said it expects 2023 revenues to be lower than the £7.8m generated last year as a result of delays to projects, many of which have been postponed to 2024.

"The healthcare industry has faced a very challenging market environment this year, especially in the second half of the year," the company said in a statement.

"In addition to other topical macro-economic headwinds, the company has seen that the biopharma clients have been restrictive on R&D outsourcing expenditure through contract research organisations."

Reduced revenues and costs associated with opening its US laboratory - which should be operational in the coming weeks - means the company will post a net loss for the full year. In 2022, it made a gross profit of £4.8m and earnings before interest, tax, depreciation and amortisation of £2.2m.

The share price was volatile after the announcement, initially slumping to a low of 4.73p, from yesterday's close of 5.26p, before rising 1.7% to 5.35p in afternoon trade.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new portfolio or transferring your portfolio from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.